Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Tongluo Jiedu prescription is a Traditional Chinese Medicine (TCM) empirical formula developed by Professor Yao Naili at Guang'anmen Hospital, China Academy of Traditional Chinese Medicine. It is specifically designed for the treatment of chronic atrophic gastritis (CAG), particularly cases involving precancerous lesions such as intestinal metaplasia and dysplasia. The prescription's name reflects its core therapeutic principles in TCM: invigorating the spleen (Jianpi), dredging the collaterals to improve microcirculation (Tongluo), and removing toxins (Jiedu). It is typically administered as an oral decoction and is being evaluated in clinical trials to support its development as a standardized hospital preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Tongluo Jiedu prescription.